UNSPSC 51282934: Orbifloxacin

This classification denotes a quinolone antibiotic with the molecular formula C19H20F3N3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 660932TPY6, chemically known as 1-cyclopropyl-7-(cis-3,5-dimethyl-1-piperazinyl)-5,6,8-trifluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid but generally known as orbifloxacin, which bears US NIH Compound Identifier 60605. European Medicines Agency schedules Orbifloxacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09454MIG.

UNSPSC 51282934 Orbifloxacin, a Commodity-tier code, nominally covers a specific veterinary antibiotic; however, the recent state and local contract opportunities tagged under this code do not reflect purchases of orbifloxacin itself. Instead, the posted solicitations involve pharmaceutical procurement (Doxycycline Hyclate and Ciprofloxacin Hydrochloride tablets) and naloxone with drug deactivation systems for public health and emergency response use. The code appears to be misaligned with actual buying activity, suggesting either a tagging error in the source data or a state and local procurement system that applies broader pharmaceutical codes to specific product line items. The scope of work evident in these opportunities encompasses bulk pharmaceutical supply through cooperative purchasing arrangements and emergency medical countermeasure procurement, but neither solicitation names orbifloxacin as a required product.

The Illinois Department of Public Health awarded a pharmaceutical warehouse piggyback contract to Chartwell Rx LLC through the MMCAP Infuse consortium for $2,999,999.11 over the contract life, with an initial 12-month term and two optional renewal years, and Seminole County, Florida issued an Invitation for Bid (IFB) on June 30, 2026, for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a July 26, 2023, response deadline. Issuing bodies include state health departments and county health authorities. Geographic activity appears concentrated in Illinois and Florida based on these records, though the small sample size and code-misalignment issue limit confidence in draw conclusions about regional concentration. Given the disconnect between the code's nominal scope and the work actually being solicited, this code warrants review of its use in state and local procurement systems before committing business development resources.